Reunion Neuroscience Inc.

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company’s lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. Reunion Neuroscience Inc. was formerly known as Field Trip Health Ltd. and changed its name to Reunion Neuroscience Inc. in August 2022. The company was incorporated in 2008 and is based in Toronto, Canada.